Gelteq Limited SEC Filings

Gelteq Limited, an Australian biotech developing gel-based drug delivery technology, reported a net loss of AUD$3.74 million for the six months ended December 31, 2025, slightly wider than the prior-year loss of AUD$3.30 million. The company generated no revenue in either period, with spending focused on research, corporate, and marketing activities.

Cash and cash equivalents fell sharply to AUD$9,349 from AUD$344,648 at June 30, 2025. Working capital showed a deficit of AUD$5.34 million, while total borrowings increased to AUD$5.11 million. To support operations, Gelteq raised equity under an equity line of credit, issued several series of convertible notes, and in May 2026 entered a securities purchase agreement providing up to US$3.5 million of additional debt funding via a 7% convertible note structure.

Gelteq Limited has called a Special Meeting of shareholders to approve issuing shares under and in connection with a new convertible note financing with an institutional investor. Approval is sought so the company can issue shares on conversion or redemption of the notes for Nasdaq Listing Rule 5635(d) and other purposes.

The notes are debt that may convert into fully paid ordinary shares using pricing formulas that can change over time. This could materially dilute existing holders and affect voting control, although the investor is contractually capped at 9.99% of issued shares at any time. The board (excluding any conflicted directors) unanimously recommends voting in favour of the resolution.

Gelteq Limited entered into a structured convertible debt financing of up to $3.5 million with an institutional investor. The company has already received an initial $1.0 million funding (net of a $150,000 original issue discount) under a convertible promissory note with a principal amount of $1,165,000, bearing 7% annual interest and maturing eighteen months from issuance.

Beginning six months after closing, the note may be redeemed into Ordinary Shares or cash at the investor’s election at a conversion price equal to 93% of the lowest five-day volume weighted average price, with a floor of $0.50 per share. A second convertible note with $2.875 million principal (net funding $2.5 million) is available on substantially similar terms, subject to shareholder approval and the absence of specified trigger events. The structure includes premium prepayment at 110% of the outstanding balance, step-up increases to the outstanding balance upon defined trigger events, and a higher 15% default interest rate if an event of default occurs.

Gelteq Limited received a notice from Nasdaq on March 18, 2026 that its ordinary shares failed to meet the minimum bid price requirement of $1.00 for 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2). The shares remain listed and continue trading under the symbol GELS.

The company has until September 14, 2026 to regain compliance. If its closing bid price is at least $1.00 for at least ten consecutive business days within this period, Nasdaq will confirm compliance. If Gelteq does not regain compliance by that date, it may qualify for an additional 180‑day grace period, potentially including actions such as a reverse stock split.

Gelteq Ltd filed an initial insider ownership report naming Paul Michael Wynne as a reporting person in his role as Chief Scientific Officer. This Form 3 establishes him as a company insider for disclosure purposes. The data shown includes no reported purchases, sales, acquisitions, or dispositions of Gelteq Ltd securities.

Gelteq Ltd director Szewach Simon H filed an initial ownership report showing indirect stakes held through family trusts. The trusts hold 338,197 Ordinary Shares and a Convertible Note issued in March 2026 with a principal amount of AUD$130,000, convertible into 65,000 Ordinary Shares at A$2.00 per share, expiring on July 1, 2026. He shares investment authority as a manager of the trustee entity and disclaims beneficial ownership beyond his pecuniary interest.

Gelteq Ltd executive Bradley Glenn Karp, Head of Sales and Marketing, filed an initial ownership report showing indirect control over 500,000 Ordinary Shares. The shares are held by trusts where he serves as manager and trustee entity, and he is a co-beneficiary. He disclaims beneficial ownership of these securities except for his pecuniary interest, and the filing does not report any new buy or sell transactions.

Gelteq Ltd Chief Executive Officer Nathan J. Givoni filed an initial Form 3 reporting indirect holdings in the company through family trusts. The filing lists 657,087 Ordinary Shares held indirectly by trust and a Convertible Note convertible into 15,000 Ordinary Shares at an exercise price of $2.0000 per share, expiring on July 1, 2026. A footnote explains he has shared investment authority as a manager of the trustee entity and is a co-beneficiary, and he disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Gelteq Limited files its Form 20-F annual report, detailing continued operating losses and substantial doubt about its ability to continue as a going concern. The company develops edible gel dosage forms and remains an early-stage business with limited sales and an unproven market. It reported total losses of approximately AUD$6,645,453 and AUD$3,546,195 for the fiscal years ended June 30, 2025 and 2024, and expects losses to continue as it funds research, product development, manufacturing and commercialization.

Management warns that significant additional financing will be required to pursue its plans, and failure to secure capital could force delays or cuts in development and marketing activities. Gelteq outsources manufacturing and relies on third-party licensees for marketing and distribution, creating supply, quality and partner-performance risks. Operations also face geopolitical and regulatory risks, including limited but growing exposure to China, heavy reliance on intangible assets, and concentrated ownership that may influence key shareholder decisions.